GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Cash Conversion Cycle

Alto Neuroscience (Alto Neuroscience) Cash Conversion Cycle : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Alto Neuroscience's Days Sales Outstanding for the three months ended in Mar. 2024 was .
Alto Neuroscience's Days Inventory for the three months ended in Mar. 2024 was .
Alto Neuroscience's Days Payable for the three months ended in Mar. 2024 was .
Therefore, Alto Neuroscience's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 0.00.


Alto Neuroscience Cash Conversion Cycle Historical Data

The historical data trend for Alto Neuroscience's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Cash Conversion Cycle Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Cash Conversion Cycle
2,598.45 - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial - - - - -

Competitive Comparison of Alto Neuroscience's Cash Conversion Cycle

For the Biotechnology subindustry, Alto Neuroscience's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Cash Conversion Cycle falls into.



Alto Neuroscience Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Alto Neuroscience's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+-
=0.00

Alto Neuroscience's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alto Neuroscience  (NYSE:ANRO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Alto Neuroscience Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus